SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments

Vista sencilla de ítem
dc.contributor.authorCanedo-Marroquín G.
dc.contributor.authorSaavedra F.
dc.contributor.authorAndrade C.A.
dc.contributor.authorBerrios R.V.
dc.contributor.authorRodríguez-Guilarte L.
dc.contributor.authorOpazo M.C.
dc.contributor.authorRiedel C.A.
dc.contributor.authorKalergis A.M.
dc.date.accessioned2021-08-05T21:08:18Z
dc.date.available2021-08-05T21:08:18Z
dc.date.issued2020-12
dc.descriptionIndexación Scopuses
dc.description.abstractThe World Health Organization (WHO) announced in March a pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This new infectious disease was named Coronavirus Disease 19 (COVID-19), and at October 2020, more than 39,000,000 cases of SARS-CoV-2 have been detected worldwide leading to near 1,100,000 deaths. Clinically, COVID-19 is characterized by clinical manifestations, such as fever, dry cough, headache, and in more severe cases, respiratory distress. Moreover, neurological-, cardiac-, and renal-related symptoms have also been described. Clinical evidence suggests that migration of immune cells to the affected organs can produce an exacerbated release of proinflammatory mediators that contribute to disease and render the immune response as a major player during the development of the COVID-19 disease. Due to the current sanitary situation, the development of vaccines is imperative. Up to the date, 42 prototypes are being tested in humans in different clinical stages, with 10 vaccine candidates undergoing evaluation in phase III clinical trials. In the same way, the search for an effective treatment to approach the most severe cases is also in constant advancement. Several potential therapies have been tested since COVID-19 was described, including antivirals, antiparasitic and immune modulators. Recently, clinical trials with hydroxychloroquine—a promising drug in the beginning—were suspended. In addition, the Food and Drug Administration (FDA) approved convalescent serum administration as a treatment for SARS-CoV-2 patients. Moreover, monoclonal antibody therapy is also under development to neutralize the virus and prevent infection. In this article, we describe the clinical manifestations and the immunological information available about COVID-19 disease. Furthermore, we discuss current therapies under study and the development of vaccines to prevent this disease. © Copyright © 2020 Canedo-Marroquín, Saavedra, Andrade, Berrios, Rodríguez-Guilarte, Opazo, Riedel and Kalergis.es
dc.description.urihttps://www.frontiersin.org/articles/10.3389/fimmu.2020.569760/full
dc.identifier.citationFrontiers in Immunology, Volume 1111 December 2020 Article number 569760es
dc.identifier.doi10.3389/fimmu.2020.569760
dc.identifier.issn16643224
dc.identifier.urihttp://repositorio.unab.cl/xmlui/handle/ria/19698
dc.language.isoenes
dc.publisherFrontiers Media S.A.es
dc.subjectCOVID-19es
dc.subjectImmune responsees
dc.subjectSARS-CoV-2es
dc.subjectTreatmentses
dc.subjectVaccineses
dc.subjectNasopharyngeal Swabses
dc.subjectSerologic Testses
dc.titleSARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatmentses
dc.typeArtículoes
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Canedo_G_SARS-COV-2_2020.pdf
Tamaño:
1.27 MB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLÉS
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
Fac.CV - Artículos de Revista